Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common cough drug dampen pain sensitivity?

NCT ID NCT02596360

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage trial asks whether dextromethorphan, a common cough suppressant, can reduce heightened pain sensitivity in healthy adults. Participants receive both dextromethorphan and a placebo on separate occasions, and researchers measure pain thresholds in skin areas that become sensitized after a mild experimental pain procedure. The goal is to see if the drug can block the amplification of pain signals, which could inform future treatments for chronic pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dextromethorphan (Pulmodexane® 30mg)
What this could lead to
If dextromethorphan reduces pain sensitivity in healthy people, it could point toward new treatments for chronic pain conditions involving central sensitization.
What could go wrong
This is a small, early-phase study in healthy volunteers, so results may not apply to people with pain conditions. Dextromethorphan can cause side effects like dizziness and drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

20 people

The number who actually took part.

Start date

Nov 2015

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male volunteers * Aged between 18 and 45 years * CYP2D6 Extensive and Intermediate metabolizers * Body mass index (BMI) between 19 and 30 kg/m2 * Systolic blood pressure between 100 and 150 mmHg, diastolic blood pressure between 50 and 90 mmHg, heart rate between 45 and 90 beats per minute * Without treatment during the 7 days before inclusion specially no use of analgesic and anti-inflammatory drugs * Cooperation and understanding enough to conform to the study obligations * Having given free informed written consent * Affiliated to the French Social Security * Inscription or acceptation of inscription in the national register of volunteers involved in trials. Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients * Lactose intolerance * Hypertension * History of stroke * Severe heart failure * Severe hepatic impairment * Shortness of breath * Congenital galactosemia, glucose-galactose malabsorption, lactase deficiency * Association with linezolid * Pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy * Diabetes (type I and II) * CYP2D6 Poor and Ultra-rapid metabolizers * AST, ALT, total bilirubin twice the average * Dextromethorphan intake during the 7 days before inclusion * Medical and surgical history incompatible with the study * Disease progression during inclusion * Excessive consumption of alcohol (\> 50g/day), tobacco (≥ 10 cigarettes/day), coffee, tea or drinks with caffeine (equivalent to more than 4 cups a day) or any addiction to drugs * Subject lacking concentration during tests training and low test results reproducibility * Subject does not meet the selection criteria for its ability to discriminate sensations to noxious stimuli during psychometric tests * Subject exclusion period, or the total allowable compensation exceeded * Subject undergoing a measure of legal protection (guardianship, supervision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Experimental pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperalgesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.